Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-007961
Filing Date
2022-05-10
Accepted
2022-05-10 07:02:08
Documents
107
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q jagx-20220331x10q.htm   iXBRL 10-Q 2236204
2 EX-31.1 jagx-20220331xex31d1.htm EX-31.1 11015
3 EX-31.2 jagx-20220331xex31d2.htm EX-31.2 11014
4 EX-32.1 jagx-20220331xex32d1.htm EX-32.1 6961
5 EX-32.2 jagx-20220331xex32d2.htm EX-32.2 6936
  Complete submission text file 0001558370-22-007961.txt   12116289

Data Files

Seq Description Document Type Size
6 EX-101.SCH jagx-20220331.xsd EX-101.SCH 115294
7 EX-101.CAL jagx-20220331_cal.xml EX-101.CAL 68132
8 EX-101.DEF jagx-20220331_def.xml EX-101.DEF 593865
9 EX-101.LAB jagx-20220331_lab.xml EX-101.LAB 818216
10 EX-101.PRE jagx-20220331_pre.xml EX-101.PRE 773621
101 EXTRACTED XBRL INSTANCE DOCUMENT jagx-20220331x10q_htm.xml XML 2072686
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36714 | Film No.: 22907295
SIC: 2834 Pharmaceutical Preparations